

# Valeriy V Breder

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5384294/publications.pdf>

Version: 2024-02-01

37  
papers

9,014  
citations

1040056

9  
h-index

940533

16  
g-index

37  
all docs

37  
docs citations

37  
times ranked

7720  
citing authors

#	ARTICLE	IF	CITATIONS
1	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2020, 382, 1894-1905.	27.0	3,828
2	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	13.7	2,771
3	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.	1.6	1,255
4	Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 862-873.	3.7	568
5	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
6	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2021, 22, 991-1001.	10.7	179
7	Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. <i>Clinical Cancer Research</i> , 2019, 25, 2088-2095.	7.0	49
8	Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. <i>Cancer</i> , 2021, 127, 865-874.	4.1	20
9	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 216-253.	0.8	19
10	Utility of cfDNA Fragmentation Patterns in Designing the Liquid Biopsy Profiling Panels to Improve Their Sensitivity. <i>Frontiers in Genetics</i> , 2019, 10, 194.	2.3	11
11	Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment. <i>Annals of Oncology</i> , 2017, 28, iii140.	1.2	5
12	Paclitaxel and cisplatin as salvage treatment in patients with non-seminomatous germ cell tumour who failed to achieve a complete remission on induction chemotherapy. <i>Clinical Oncology</i> , 1998, 10, 297-300.	1.4	3
13	Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors. <i>Meditinskiy Sovet</i> , 2020, , 16-24.	0.5	2
14	Second-line treatment of hepatocellular carcinoma: from theory to practical issues. <i>Meditinskiy Sovet</i> , 2019, , 30-36.	0.5	2
15	Systemic therapy of hepatocellular carcinoma: reality and prospects. <i>Annals of HPB Surgery</i> , 2020, 25, 27-38.	0.5	2
16	Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping. <i>Meditinskiy Sovet</i> , 2021, , 154-159.	0.5	1
17	Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center. <i>Meditinskiy Sovet</i> , 2019, , 16-21.	0.5	1
18	Predictive Factors for the Effectiveness of Repeated Lines of Transarterial Chemoembolization in the Treatment of Localized Hepatocellular Carcinoma. <i>Journal of Oncology Diagnostic Radiology and Radiotherapy</i> , 2021, 4, 42-52.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Intermediate Stage Hepatocellular Carcinoma Classifications: the Review. Journal of Oncology Diagnostic Radiology and Radiotherapy, 2021, 4, 53-64.	0.2	0
20	Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center. Meditsinskiy Sovet, 2021, , 18-24.	0.5	0
21	Multidisciplinary approach in hepatocellular carcinoma progression treatment after liver transplantation: the first experience in Russia. Annals of HPB Surgery, 2019, 24, 65-73.	0.5	0
22	Will neo-adjuvant immunotherapy become a new paradigm in the treatment of lung cancer patients. Meditsinskiy Sovet, 2019, , 22-29.	0.5	0
23	Stereotactic hypofractionate radiotherapy in the treatment of patients with lung cancer. Meditsinskiy Sovet, 2020, , 150-156.	0.5	0
24	Radiation Therapy in Complex Treatment of Patients with Pleural Mesothelioma. Journal of Oncology Diagnostic Radiology and Radiotherapy, 2020, 3, 9-17.	0.2	0
25	Fibrolamellar liver cancer: the modern concept. Meditsinskiy Sovet, 2020, , 134-142.	0.5	0
26	Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy. Meditsinskiy Sovet, 2020, , 194-198.	0.5	0
27	Oncological care for the patients with hepatocellular carcinoma in COVID-19 pandemic. Meditsinskiy Sovet, 2020, , 226-231.	0.5	0
28	Firsthand experience of chemoradiotherapy in patients with localized small cell lung cancer. Retrospective assessment. Meditsinskiy Sovet, 2020, , 190-195.	0.5	0
29	The role of radiation therapy in the treatment of patients with pleural mesothelioma. Journal of Modern Oncology, 2020, 22, 109-114.	0.3	0
30	Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives. Journal of Modern Oncology, 2021, 23, 428-435.	0.3	0
31	Clinical prognostic factors for fibrolamellar liver carcinoma. Russian Journal of Oncology, 2021, 26, 13-22.	0.1	0
32	Features of modified response evaluation criteria use in solid tumors in patients with hepatocellular carcinoma. Annals of HPB Surgery, 2022, 27, 33-39.	0.5	0
33	Đembrolizumab as second line therapy for hepatocellular patient. Meditsinskiy Sovet, 2021, , 150-154.	0.5	0
34	Prognostic value of the proportion of the sclerosing component in fibrolamellar liver carcinoma. Meditsinskiy Sovet, 2021, , 94-100.	0.5	0
35	Neoadjuvant therapy bridging patients with hepatocellular cancer waiting for liver transplant. Meditsinskiy Sovet, 2021, , 110-116.	0.5	0
36	Resolution on the results of Advisory Board "Searching the effective methods of testing and treating patients with NSCLC caused by <i>NTRK</i> gene fusions". Meditsinskiy Sovet, 2022, , 50-56.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma. Meditsinskiy Sovet, 2022, , 157-162.	0.5	0